Clinical Trial Detail

NCT ID NCT02697591
Title An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

renal cell carcinoma

Advanced Solid Tumor

melanoma

endometrial adenocarcinoma

Therapies

INCAGN01876

Age Groups: adult

No variant requirements are available.